FAAH and hypertensive disorder: The antihypertensive potential of the endocannabinoid-degrading enzyme FAAH has been demonstrated to depend on the hypertension model, with more pronounced changes in, for example, the DOCA-salt model [1,20], including vascular changes that were at least partially responsible for the drop in blood pressure [4].